Henry Schein, Inc. (HSIC) Presents at Leerink Global Healthcare Conference 2026 Transcript

Event: Henry Schein announced Fred Lowery as its new CEO — the company's fourth CEO in 94 years — discussed by CFO Ron South at the Leerink Global Healthcare Conference. Commentary emphasized continuity of culture and values but offered no material financial guidance, operational changes, or near-term catalysts likely to move the stock.

Analysis

A pivot toward higher-margin recurring services and software could materially re-rate Henry Schein’s earnings power even if top-line growth stays mid-single digits. If management can shift ~3–6% of revenue into services over 18–24 months, expect a 150–350bp expansion in adjusted operating margin via higher gross margin and lower variable SG&A as a percent of revenue; that math supports 20–35% upside in EV/EBITDA multiple assumptions versus a pure-distributor baseline.

Second-order winners include niche software vendors and labs that plug into a scaled services platform — those partners get distribution + data flywheel access, increasing their valuation multiples. Conversely, thin-margin independent distributors and vendors that depend on transactional volume (private-label/low-tech suppliers) face margin compression and tougher payment terms; a 1–2% working-capital optimization at scale would mechanically free up hundreds of millions of dollars of cash on a $10–15B revenue base, enabling bolt-on M&A or buybacks.

Near-term risks: execution on integration, customer churn from aggressive cost takeouts, and inventory normalization can create earnings volatility over the next 2–6 quarters. Key catalysts that will validate the thesis are a clear services ARR cadence, disclosed cross-sell KPIs, an investor day with 24-month targets, and any bolt-on M&A; failure to show progress on these within 3–6 quarters should be viewed as a reversal trigger.

Key Decisions for Investors

• Long HSIC equity (12–18 months): buy HSIC shares with a 20% trailing stop; target 30–40% total return if management reports 200–300bp margin expansion within 12 months. Position size: 2–4% of risk capital.
• Long HSIC call spread (12 months) to skew risk/reward: buy a 12-month call and sell a higher strike to finance premium (target net cost ≈ 30–40% of full upside). Objective: 2:1 upside/downside vs premium; max loss = premium paid, target return ≥50% if thesis plays out.
• Pair trade (12 months): long HSIC / short PDCO (or closest pure-play distributor) to isolate margin-expansion vs sector cyclical risk. Size long:short 1:1 by notional; expect relative outperformance of 15–25% if services mix accelerates; risk = industry-wide recovery helping both names.
• Hedge: buy 3–6 month HSIC puts (or collar equity position) ahead of the first major strategic update to protect against a 15–25% downside from execution disappointments. Cost should be sized to limit portfolio drawdown to <3% of NAV.